Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia
Authors:
- Sapana PrajapatiSPSapana Prajapati
- Pei LinPLPei Lin
Open Access
Abstract
BACKGROUND.: Rarely, patients who present with pancytopenia and are diagnosed initially with aplastic anemia (AA) subsequently develop a myelodysplastic syndrome (MDS). There has been controversy regarding whether the initial diagnosis of AA is correct or whether these patients have hypocellular MDS at the onset of pancytopenia.METHODS.: The authors studied bone marrow (BM) specimens from patients who were diagnosed initially with AA and subsequently with MDS from a cohort of 128 consecutive patients who had AA during the period from 1993 to 2004. Cytogenetic and fluorescence in situ hybridization (FISH) analyses were performed to assess for monosomy 7 retrospectively in a subset of patients.RESULTS.: Twelve patients were identified (age range, 26–79 years). At the time they were diagnosed with AA, there was no evidence of dysplasia, the median BM cellularity was 5% (range, from <1% to 15%), and all patients had a normal karyotype. Therapy for 11 patients included immunomodulating agents, which were accompanied by growth factors in 4 patients and 1 patient underwent BM transplantation. One patient received growth factors only. The median interval to the diagnosis of MDS was 9 months (range, 2–43 months). The median BM cellularity was 30% (range, 5–90%), and dysplastic changes were observed in all patients. Nine patients had an abnormal karyotype, and monosomy 7 was the most common abnormality (n = 5 patients). FISH detected monosomy 7 in 6 samples at the time MDS was diagnosed and in 2 samples at the time AA was diagnosed.CONCLUSIONS.: The detection of monosomy 7 in specimens that were considered AA and the short time interval to a subsequent diagnosis of MDS suggests that these patients had hypoplastic MDS at the onset of pancytopenia. Therapy may allow the detection of MDS by enhancing cell growth. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 33 references indexed in Scilit:
- Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)Blood, 2006
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptorProceedings of the National Academy of Sciences, 2006
- MALT1 gene rearrangements and NF-κB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breastLaboratory Investigation, 2006
- Genomic instability in bone marrow failure syndromesAmerican Journal of Hematology, 2004
- Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosisBritish Journal of Haematology, 2002
- Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experienceKlinische Padiatrie, 1998
- Trilineage recovery by combination therapy with recombinant human granulocyte colony‐stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemiaStem Cells, 1994
- Multilineage response in aplastic anemia patients following long‐term administration of filgrastim (recombinant human granulocyte colony stimulating factor)Stem Cells, 1993
- Stimulation of Myelopoiesis in Patients with Aplastic Anemia by Recombinant Human Granulocyte-Macrophage Colony-Stimulating FactorNew England Journal of Medicine, 1988